Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10103729 | 0.80 | — | — | |
| SCHEMBL440888 | 0.80 | — | — | |
| SCHEMBL469229 | 0.80 | — | — | |
| SCHEMBL20852783 | 0.80 | — | — | |
| SCHEMBL10192262 | 0.72 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL469194 | 0.72 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL469207 | 0.72 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL10153379 | 0.72 | MAPT (0.30) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL10153402 | 0.72 | MAPT (0.30) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL10193168 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | MAPT 3986/4885CYP2C9 3902/4885CYP2C19 3558/4885 |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | MAPT 4011/4885CYP2C9 4126/4885CYP2C19 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.